Compare Stocks

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTX Crescita Therapeutics	C$0.42	C$0.43	C$0.36 ▼ C$0.73	C$8.21M	1.66	18,433 shs	1,173 shs
QPT AdvisorShares Q Portfolio Blended Allocation ETF	$19.10 +0.1%	$19.10	$18.63 ▼ $27.54	$1.91M	N/A	1,912 shs	19,400 shs
VAL Valaris	$67.95 -2.0%	$69.23	$54.13 ▼ $78.92	$5.02B	1.13	902,173 shs	660,809 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTX Crescita Therapeutics	0.00%	0.00%	+5.00%	-22.22%	-40.85%
QPT AdvisorShares Q Portfolio Blended Allocation ETF	0.00%	0.00%	0.00%	0.00%	0.00%
VAL Valaris	-1.96%	-6.57%	-4.40%	+2.44%	+1.48%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VAL Valaris	3.2812 of 5 stars	3.5	2.0	0.0	0.0	1.8	1.7	3.1

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	0.00	N/A	N/A	N/A
VAL Valaris	3.00	Buy	$100.00	47.17% Upside

Current Analyst Ratings

Latest QPT, HVO, CTX, RLM, and VAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/5/2024	VAL Valaris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
2/23/2024	VAL Valaris	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$107.00 ➝ $105.00
2/14/2024	VAL Valaris	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$106.00 ➝ $105.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTX Crescita Therapeutics	C$17.52M	0.47	C$0.35 per share	1.20	C$0.94 per share	0.45
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A	N/A	N/A	N/A
VAL Valaris	$1.78B	2.76	$2.46 per share	27.66	$27.40 per share	2.48

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTX Crescita Therapeutics	-C$1.99M	-C$0.10	N/A	∞	N/A	-11.33%	-9.95%	-4.61%	5/9/2024 (Estimated)
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VAL Valaris	$865.40M	$11.69	5.81	6.55	N/A	48.50%	5.71%	2.40%	5/2/2024 (Confirmed)

Latest QPT, HVO, CTX, RLM, and VAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/2/2024	N/A	VAL Valaris	$0.40	N/A	-$0.40	N/A	N/A	N/A
2/21/2024	Q4 2023	VAL Valaris	$0.29	$0.61	+$0.32	-$10.08	$484.00 million	$483.80 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTX Crescita Therapeutics	N/A	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	$0.08	0.42%	N/A	N/A	N/A
VAL Valaris	$1.48	2.18%	N/A	12.66%	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTX Crescita Therapeutics	6.66	3.80	2.29
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A
VAL Valaris	0.54	1.71	1.71

Ownership

Institutional Ownership

Company	Institutional Ownership
CTX Crescita Therapeutics	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A
VAL Valaris	96.74%

Insider Ownership

Company	Insider Ownership
CTX Crescita Therapeutics	10.32%
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A
VAL Valaris	0.11%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CTX Crescita Therapeutics	62	19.54 million	N/A	Not Optionable
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	100,000	N/A	Not Optionable
VAL Valaris	5,985	72.41 million	72.33 million	Optionable

QPT, HVO, CTX, RLM, and VAL Headlines

Source	Headline
	Interocean announces UT technology demonstration zawya.com - April 16 at 8:33 AM
	Mutual of America Capital Management LLC Acquires 38,367 Shares of Valaris Limited (NYSE:VAL) marketbeat.com - April 14 at 6:11 AM
	Valaris Schedules First Quarter 2024 Earnings Release and Conference Call businesswire.com - April 11 at 4:30 PM
	Aramco Suspends Valaris Rig Contract rigzone.com - April 11 at 1:38 AM
	Valaris (VAL) Receives Rig's Suspension Notice From Aramco zacks.com - April 9 at 2:26 PM
	Lancaster Investment Management Buys Shares of 400,116 Valaris Limited (NYSE:VAL) marketbeat.com - April 9 at 12:12 PM
	Port Everglades marks commissioning of new container cranes en.portnews.ru - April 7 at 11:30 AM
	Valaris faces rig suspension in Saudi joint venture investing.com - April 6 at 2:41 AM
	Aramco Suspends Another Jack-Up Rig oedigital.com - April 5 at 4:40 PM
	Suspension notice for Valaris joint venture royalgazette.com - April 5 at 4:40 PM
	Saudi Aramco suspends offshore rig deal with New York-listed player upstreamonline.com - April 5 at 1:44 AM
	Aramco suspends jackup contract with offshore driller upstreamonline.com - April 4 at 8:43 PM
	Valaris (NYSE:VAL) Shares Gap Down to $76.66 marketbeat.com - April 4 at 2:02 PM
	Valaris Limited (NYSE:VAL) Shares Purchased by Vanguard Group Inc. marketbeat.com - April 3 at 4:09 AM
	Valaris: Buy Despite Near-Term Jackup Market Headwinds seekingalpha.com - April 2 at 7:31 PM
	VAL Quantitative Stock Analysis nasdaq.com - April 1 at 6:26 PM
	Valaris Limited (NYSE:VAL) Receives Consensus Recommendation of "Buy" from Analysts marketbeat.com - April 1 at 4:14 AM
	Four-way race in heated Petrobras tender for well intervention vessels upstreamonline.com - March 28 at 4:58 PM
	Esgian Week 12 Report: New Finds in Guyana, China and Norway marinelink.com - March 24 at 9:59 PM
	Wellington Management Group LLP Purchases 107,008 Shares of Valaris Limited (NYSE:VAL) marketbeat.com - March 20 at 4:39 AM
	Activists Across 6 Countries Stage Day of Action Against North Sea Oil Drilling truthout.org - March 17 at 2:06 PM
	'North Sea Fossil Free': Activists in 6 Countries Protest 'Unhinged' Oil and Gas Development commondreams.org - March 16 at 10:22 PM
	'Scaling innovation': Offshore players invest in carbon capture, efficiency and electrification upgrades upstreamonline.com - March 13 at 5:44 PM
	Perenco Starts Gas Production in Southern North Sea oedigital.com - March 11 at 5:54 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
ASML’s Earnings Could Bring The Stock to New Highs
April 16, 2024 10:20 AM
View ASML’s Earnings Could Bring The Stock to New Highs

All Headlines

Company Descriptions

Crescita Therapeutics

TSE:CTX

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

AdvisorShares Q Portfolio Blended Allocation ETF

NYSEARCA:QPT

Valaris

NYSE:VAL

Valaris Limited, together with its subsidiaries, provides offshore contract drilling services Gulf of Mexico, South America, North Sea, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Floaters, Jackups, ARO, and Other. It owns an offshore drilling rig fleet, which include drillships, dynamically positioned semisubmersible rigs, moored semisubmersible rig, and jackup rigs. It serves international, government-owned, and independent oil and gas. Valaris Limited was founded in 1975 and is based in Hamilton, Bermuda.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial